The mission of Zhejiang Key Laboratory of Radiation Oncology is to contribute to the prevention and elimination of cancer through innovative basic radiobiological research and clinical translational research.
Our vision is to be an influential platform for translational research and academic exchange in the field of radiation oncology, recognized for our innovative science and the excellence of our people.
Zhejiang key Laboratory of Radiation Oncology, relying on Cancer Hospital of the University of Chinese Academy of Sciences (CHUCAS, Zhejiang Cancer Hospital), was established in July 2013 by Science Technology Department of Zhejiang Province. 66 researchers are members of the lab. Professor Ming Chen served as the director of the laboratory, and Professor Jinming Yu, academician of the Chinese Academy of Engineering, served as director of the academic Committee. The lab occupies roughly 3,300 square meters, and consists of radiophysics laboratory, radiobiology laboratory and radiotherapy clinical laboratory. The lab has the most advanced IGRT small animal irradiator, small animal living imager, high-throughput sequencer, flow cytometry etc., with a total value of 31.75 million yuan.
At present, it relies on the laboratory to carry out 15 national funding projects, 24 provincial projects, and more than 50 other research projects, with a total research funding of more than 35 million yuan. Laboratory members have won 7 scientific and technological awards, 66 intellectual property rights, rewrote 4 American NCCN guidelines, and published more than 250 papers, including more than 160 SCI papers.
The lab holds annual spring/autumn seminars and basic training courses on radiation physics and radiotherapy techniques. In order to promote rapid development and to achieve the opening benefits of the lab, we warmly welcome members and non-members to participate in academic communication and research work.
Zhejiang key Laboratory of Diagnosis and Therapeutics of Thoracic Cancer (lung, esophagus) (Thoracic Lab for abbreviation), is established on November 2011 by the Science & Technology Council of Zhejiang Province, the lab is associated with Zhejiang Cancer Hospital. The Thoracic lab includes 68 core members, comprised with 7 research platforms headed by PIs.
Lung cancer and esophageal cancer are the major cancers of interests of the Thoracic lab. The researches of the lab focused on translational thoracic cancer research, cancer diagnosis and therapeutics. Such researches are promoting personalized cancer treatment and precision cancer therapeutics in combination of multi-disciplinary strategy for cancer treatment, which improve the quality and efficacy for cancer treatment. In cooperation with Zhejiang Cancer center and the office of Zhejiang Cancer Prevention & Diagnosis the lab engages with broad social and academic communication and exchange programs to improve the services of primary hospitals for the common wellness of the better prevention and early diagnosis of cancer.
The foundations of Thoracic Lab are supported bythe National Natural Science Foundation of China, the Major State Basic Research Development Program of China, the Key Project of Science and Technology of Zhejiang and etc. In the last three years, representational studies have been published in journals such as JAMA, Nature Communications, Annals of Oncology, Clinical Cancer Research and Journal of Thoracic Oncology. The lab is awarded with 1st and 2st Prizes ofNational science and technology progress award and 1st Prizes of Zhejiang provincial science and technology progress award.
Zhejiang Key Laboratory of Head & Neck Cancer Translational Research is a leading laboratory of head and neck tumors that focuses on translational studies of H&N cancers, in China. The research interests of our laboratory include thyroid carcinoma, H&N mucosal squamous cell carcinoma, and salivary gland tumor. The laboratory is led by the academic committee and has made significant progresses in multidisciplinary therapeutic model, targeted therapy of refractory thyroid carcinoma, and functional preservation and precision reconstruction of H&N cancer, and comprises with:
1.Clinical sample bank, which provide H&N tumors for the research of the whole lab.
2. Cell and molecular biology center, which concentrates on the basic and translational research of H&N tumors and has made important research findings on thyroid carcinoma and salivary gland neoplasm.
3. Surgical technique center, including microsurgery, 3D-reconstruction labs and endoscopic, which works on microvascular anastomosis and nerve repair research, precision reconstruction research for postoperative defects by using computer and digital technology, and cosmetic neck surgery research.
4. Clinical pharmacy center, which focuses on key factors that influence efficacy of anti-tumor drugs and adverse reactions. Using research methods of pharmacogenetics, pharmacokinetics and pharmacodynamics, bioinformatics to screen the best treatment plan and promote the combination of basic research and clinical practice to provide basis for clinical individualized medication of H&N carcinoma.
5. Nuclear medicine center, which works on basic research of differentiated thyroid cancer by tumor genomics, and the therapy of iodine resistance thyroid cancer.
In the last three years (2017-2019), the lab has made remarkable achievements, including undertook 23 research projects, published 82 SCI cited papers, awarded with 2 Science & Technology Progress Awards. By national and international cooperation, the center has made an impact on the molecular genetic mechanism, personalized treatment, surgical precision reconstruction, early diagnosis of thyroid carcinoma, mucosal squamous cell carcinoma, and salivary gland neoplasm. At the same time, the center provides a conductive environment for all researchers of H&N cancers in Zhejiang province, promoting the researches in the field.
Zhejiang Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine on Cancer was established in 2005 with the approval of Zhejiang Administration of Traditional Chinese Medicine and affiliated to Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital). At present, Professor QinghuaYao, chairman of Zhejiang Cancer Committee of Integrated Traditional Chinese and Western Medicine, is the director of the laboratory, with ProfessorsWei Chen, Ping Huang and Aiqin Zhang as the deputy directors.The board of the academic committee has nine distinguished experts including Professor Zhihua Liu, deputy director of the State Key Laboratory of Molecular Oncology and Professor Hongsheng Lin from Guang'an Men Hospital of Chinese Academy of Traditional Chinese Medicine. So far, there are 54 staff members in the laboratory. Among them, 29 have senior professional titles, 20 have intermediate professional titles, and 5 have junior professional titles, 13 have doctoral degree, 23 have master's degrees, and many members have overseas study experience.
The laboratory is mainly responsible for the basic and clinical research on the treatment of cancer with the combination of traditional Chinese and Western medicine, including the synergistic and toxic reducing effects of traditional Chinese medicine on anticancer treatment (radiotherapy,chemotherapy, targeted treatment and immunotherapy); the molecular mechanism study on anti-metastasis, immune regulation, intestinal microecology regulation of traditional Chinese medicine; the internal mechanism of multi-target prevention and treatment of cancer with traditional Chinese medicine; the research on traditional Chinese medicine Syndromes of cancer.In addition, laboratory members have established the first cancer nutritional support therapymedical team in the province, and carried out the clinical and scientific research of cancer risk screening and nutritional support treatment. At present, the laboratory and Ghent University of Belgium have carried out close, in-depth and comprehensive cooperation on the in vitro simulation technology of traditional Chinese medicine on intestinal microecology and whole gastrointestinal tract.
The laboratory has undertaken 62 scientific research projects, including 6 from national funding agencies, 13 from provincial and ministerial agencies, and 43 from municipal agencies. The laboratory won 36 scientific research awards, including 7 provincial and ministerial grade and 29 municipal grade.The laboratory has published 164 academic papers, including 85 SCI papers, 47 in Chinese series and 32 in other core journals.The laboratory has published 10 worksand has been authorized 26 patents.
Through the continuous investment and construction inrecent years, with the molecular mechanism and key technologies of cancer prevention and treatment of traditional Chinese and Western medicine as the scientific issues, supported by clinical medicine, basic medicine and traditional Chinese medicine disciplines, we will comprehensively improve the scientific and technological innovation ability of traditional Chinese and Western medicine in cancer prevention and treatment. The goal of the laboratory is to make original research breakthrough, integrate cancertreatment, traditional Chinese medicine treatment and nutrition treatment as a whole, aim at the forefront of this field, carry out research from basic to clinical, from individual prevention to precise treatment, properly integrate cancer treatment of traditional Chinese and Western medicine, comprehensively improve the level of cancer prevention and treatment technology of integrated traditional Chinese and Western medicine, and the enhance academic status and influence of the research on integrated traditional Chineseand Western medicine in Zhejiang province both domestically and internationally.